Stryker Corporation (SYK) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Stryker Corporation (SYK) Healthcare & Pipeline Overview

Stryker Corporation stands as a prominent player in the medical technology sector, delivering advanced surgical equipment and orthopedic implants while maintaining a robust market presence in over 75 countries.

What Is the Investment Thesis for SYK?

Stryker Corporation is positioned for sustained growth, driven by its diverse product offerings and strong market presence. The company boasts a market capitalization of $131B and a P/E ratio of 35.2, reflecting investor confidence in its future performance. With a profit margin of 13.2% and a gross margin of 63.7%, Stryker demonstrates operational efficiency that exceeds industry averages. Key growth catalysts include the increasing demand for orthopedic procedures, driven by an aging population and rising prevalence of chronic conditions. Furthermore, ongoing innovations in neurotechnology and minimally invasive surgical techniques are expected to expand market opportunities. The company's commitment to R&D will likely yield new products that meet evolving healthcare needs. However, potential risks include regulatory challenges and competition from other medical device manufacturers, which could impact market share and pricing strategies. Overall, Stryker's strong fundamentals and strategic initiatives position it well for long-term growth.

Based on FMP financials and quantitative analysis

SYK Key Highlights

Market capitalization of $131B reflects strong investor confidence.

• P/E ratio of 35.2 indicates premium valuation compared to industry peers.
• Profit margin of 13.2% showcases operational efficiency.
• Gross margin of 63.7% exceeds the industry average, indicating strong pricing power.
• Dividend yield of 1.21% provides a steady income stream for investors.

Who Are SYK's Competitors?

SYK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SYK's Key Strengths?

Leading position in the medical technology sector with a strong brand.

• Diverse product portfolio addressing various medical needs.
• Robust financial performance with high profit and gross margins.
• Strong commitment to research and development fostering innovation.

What Are SYK's Weaknesses?

High dependency on the orthopedic product segment for revenue.

• Potential exposure to regulatory changes impacting product approvals.
• Significant competition from established medical device manufacturers.
• Challenges in managing supply chain disruptions and costs.

What Could Drive SYK Stock Higher?

SYK catalyst: Launch of new orthopedic products expected to enhance market share in the growing joint replacement market.

• Expansion into emerging markets continues to drive revenue growth and increase global footprint.
• Anticipated regulatory approvals for innovative neurotechnology products set to broaden product offerings.
• Strategic partnerships with healthcare providers to enhance product distribution and market penetration.
• Increased investment in R&D aimed at developing next-generation medical devices.

What Are the Key Risks for SYK?

Rich valuation — a P/E of 35.2 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $106.0M recently.
• Regulatory changes could impact product approval timelines and market entry.
• Intense competition from established medical device manufacturers may pressure pricing and market share.
• Economic downturns could lead to reduced healthcare spending and impact sales.
• Supply chain disruptions may affect production and delivery of medical devices.

What Are the Growth Opportunities for SYK?

• Growth opportunity 1: The orthopedic market is projected to grow significantly, with an estimated CAGR of 6.1% through 2028, driven by an aging population and increased incidence of joint disorders. Stryker's extensive range of orthopedic implants positions it to capture a larger market share as demand for joint replacement surgeries rises.
• Stryker's innovative products for minimally invasive surgical techniques and neurovascular interventions place it at the forefront of this growing market, enhancing its revenue potential.
• Growth opportunity 3: The global market for surgical equipment is anticipated to grow at a CAGR of 5.5% through 2026. Stryker's comprehensive portfolio of surgical navigation systems and emergency medical equipment positions it to benefit from the increasing demand for advanced surgical solutions in hospitals and healthcare facilities.
• Growth opportunity 4: The rise of telemedicine and digital health solutions is transforming the healthcare landscape, creating opportunities for Stryker to integrate technology into its product offerings. By leveraging digital tools, the company can enhance its surgical equipment and patient handling systems, driving future growth.
• Growth opportunity 5: Expansion into emerging markets presents a significant growth opportunity for Stryker. With increasing healthcare expenditures and a rising demand for medical devices in regions such as Asia-Pacific and Latin America, Stryker can capitalize on these trends to expand its global footprint.

What Threats Does SYK Face?

• Intense competition leading to pricing pressures in the medical device market.
• Regulatory challenges affecting product development and market entry.
• Economic downturns impacting healthcare spending and budgets.
• Rapid technological advancements necessitating continuous innovation.

What Are SYK's Competitive Advantages?

• Strong brand recognition and reputation for quality and innovation in medical devices.
• Extensive patent portfolio protecting proprietary technologies and products.
• Established relationships with healthcare providers and institutions worldwide.
• Robust investment in research and development driving continuous innovation.
• Diverse product offerings catering to various medical specialties, reducing reliance on a single market.

What Does SYK Do?

Founded in 1941, Stryker Corporation has evolved into a global leader in medical technology, headquartered in Kalamazoo, Michigan. The company operates primarily through two segments: MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment focuses on providing a wide array of implants for hip and knee joint replacements, as well as trauma and extremities surgeries. Additionally, it offers spinal implant products, including cervical, thoracolumbar, and interbody systems designed for spinal injuries, deformities, and degenerative therapies. Meanwhile, the MedSurg and Neurotechnology segment encompasses surgical equipment, navigation systems, and emergency medical devices, catering to various medical specialties. Stryker's neurotechnology products include minimally invasive solutions for endovascular techniques and surgical procedures related to brain and skull surgeries. The company emphasizes innovation, continuously developing advanced orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation solutions. Stryker's products are distributed through company-owned subsidiaries and third-party dealers across approximately 75 countries, solidifying its position as a trusted partner for healthcare providers. Over the decades, Stryker has grown significantly, driven by strategic acquisitions and a commitment to research and development, ensuring it remains at the forefront of medical technology advancements.

What Products and Services Does SYK Offer?

• Develops and manufactures advanced medical devices and surgical equipment.
• Offers orthopedic implants for joint replacements and trauma surgeries.
• Provides neurotechnology products for brain and spinal surgeries.
• Supplies surgical navigation systems and emergency medical equipment.
• Delivers innovative biosurgery and orthobiologic products.
• Distributes products through subsidiaries and third-party dealers in 75 countries.

How Does SYK Make Money?

• Generates revenue through the sale of medical devices and surgical equipment.
• Offers a diverse product portfolio catering to various medical specialties.
• Engages in strategic partnerships and collaborations to enhance product offerings.
• Invests in research and development to drive innovation and product advancement.
• Utilizes a global distribution network to reach healthcare providers effectively.

What Industry Does SYK Operate In?

The medical devices industry is experiencing robust growth, driven by technological advancements and an increasing demand for innovative healthcare solutions. The global medical device market is projected to reach approximately $600 billion by 2027, with a CAGR of around 5.4%. Stryker Corporation is well-positioned within this landscape, competing with major players such as Amgen Inc. (AMGN), Gilead Sciences, Inc. (GILD), Pfizer Inc. (PFE), Danaher Corporation (DHR), and Sanofi (SNY). The company's focus on orthopedic and neurotechnology products aligns with market trends emphasizing minimally invasive procedures and enhanced patient outcomes, solidifying its competitive advantage in a rapidly evolving industry.

Who Are SYK's Key Customers?

• Hospitals and healthcare facilities seeking advanced medical devices.
• Surgeons and medical professionals requiring innovative surgical equipment.
• Emergency medical services utilizing patient handling and emergency equipment.
• Healthcare providers in emerging markets looking for cost-effective solutions.
• Research institutions collaborating on medical technology advancements.

Stryker Corporation (SYK) Valuation Context

Valued at $131B, SYK is classified as a large-cap stock. Relative to its peer group, SYK's quantitative score of 79/100 is above the peer average of 68/100.

SYK Revenue & Earnings Trend

In Q2 2026, SYK generated $6.59B in top-line revenue, marking a sequential increase of 9.5%. The company recorded net income of $1.28B, with diluted EPS of $3.30. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SYK averaged $2.41 in diluted EPS.

Company Profile

Stryker Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Portage, US. The company is led by CEO Kevin A. Lobo. SYK has traded publicly since 1980.

Return on equity for Stryker Corporation stands at 16.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.8%, showing how much profit it generates from its asset base. SYK trades at a trailing price-to-earnings ratio of 35.20, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.8%, the inverse of the P/E and a quick read on earnings relative to price.

Stryker Corporation's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.92 places it in the safe zone, indicating low near-term bankruptcy risk.

Stryker Corporation has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 1.3% above estimates on average.

Wall Street analysts project Stryker Corporation revenue of about $27.28B for fiscal 2026, with EPS near $15.00. The estimate reflects 20 contributing analysts.

Over the past six months, Stryker Corporation insiders filed 30 SEC Form 4 transactions — 23 sales and 7 purchases. On net that is roughly 339K shares disposed (about $106.0M), a signal worth weighing alongside the fundamentals.

SYK Financials

SYK earnings history & estimates →

SYK Latest News

SYK Analyst Consensus

SYK MoonshotScore

Latest Stryker Corporation Analysis

What Investors Ask About Stryker Corporation (SYK) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources